Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-2025
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrügger, Urs-
dc.contributor.authorRuckstuhl, Andreas-
dc.contributor.authorHorisberger, Bruno-
dc.contributor.authorGratwohl, Alois-
dc.date.accessioned2018-06-25T14:18:49Z-
dc.date.available2018-06-25T14:18:49Z-
dc.date.issued2014-08-07-
dc.identifier.issn0266-4623de_CH
dc.identifier.issn1471-6348de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/7264-
dc.description.abstractObjectives: The aim of this study was to assess incidence, time frame, and outcome of “Coverage with Evidence Development” (CED) decisions in the Swiss Basic Health Insurance scheme. Methods: Analysis of all controversial medical technologies submitted to review by the Swiss Federal Office of Public Health (FOPH) from 1996 to 2012 with focus on decisions with constraints. Description of types of technology, type of initial decision, duration of evaluation period, final decision, and search for potential factors associated with changes over time. Results: Forty-five (37.5 percent) of 120 controversial health technologies were classified as “yes, in evaluation, reimbursed” for a certain period of time and thirty-five (29.2 percent) as “no, in evaluation, not reimbursed” by the Federal Department of Home Affairs from 1996 to 2012. The rate of CED decisions ranged between zero and nine per year and was influenced by type of technology and calendar year. Forty-four of forty-five decisions were subject to further restrictions, to a “center or a specialist” (76 percent), “indications” (49 percent), “registry” (31 percent), or “other” (49 percent). The time to a final decision ranged from 1.5 to 11 years (median, 6 years). No factors associated with initial decision and final outcome could be identified. Conclusions: CED as a reality in Switzerland might have enabled patients to obtain access to promising technologies early in their life cycle. CED might have acted as a trigger to a successful implementation of a comprehensive national registry. The lack of qualitative data stresses the urgent need for evaluation of the HTA decisions and their impact on patient outcome and costs.de_CH
dc.language.isoende_CH
dc.publisherCambridge University Pressde_CH
dc.relation.ispartofInternational Journal of Technology Assessment in Health Carede_CH
dc.rightshttp://creativecommons.org/licenses/by-nc-sa/3.0/de_CH
dc.subjectHealth technology assessmentde_CH
dc.subjectCoverage with evidence developmentde_CH
dc.subject.ddc610: Medizin und Gesundheitde_CH
dc.titleDevelopment of coverage with evidence development for medical technologies in Switzerland from 1996 to 2012de_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementSchool of Engineeringde_CH
zhaw.organisationalunitInstitut für Datenanalyse und Prozessdesign (IDP)de_CH
dc.identifier.doi10.21256/zhaw-2025-
dc.identifier.doi10.1017/S0266462314000233de_CH
zhaw.funding.euNode_CH
zhaw.issue3de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end259de_CH
zhaw.pages.start253de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume30de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
Appears in collections:Publikationen School of Engineering

Files in This Item:
File Description SizeFormat 
2014_Ruckstuhl_development_of_coverage_with_evidence.pdf252.1 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.